Edap Tms S.A. (NASDAQ:EDAP) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research note issued to investors on Tuesday. <\/p>\n
According to Zacks, EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. <\/p>\n
Separately, TheStreet upgraded Edap Tms from a sell rating to a hold rating in a research note on Tuesday, September 27th. <\/p>\n
Edap Tms (NASDAQ:EDAP) traded up 1.83% during midday trading on Tuesday, reaching $3.34. 39,022 shares of the company were exchanged. The company has a market capitalization of $95.95 million, a price-to-earnings ratio of 8.46 and a beta of 1.29. The company has a 50 day moving average of $3.15 and a 200-day moving average of $3.03. Edap Tms has a 52-week low of $2.43 and a 52-week high of $4.80. <\/p>\n
An institutional investor recently raised its position in Edap Tms stock. Wells Fargo & Company MN increased its stake in Edap Tms S.A. (NASDAQ:EDAP) by 1.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 193,655 shares of the companys stock after buying an additional 2,000 shares during the period. Wells Fargo & Company MN owned approximately 0.67% of Edap Tms worth $562,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.56% of the companys stock. <\/p>\n
About Edap Tms <\/p>\n
EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors. <\/p>\n
Get a free copy of the Zacks research report on Edap Tms (EDAP) <\/p>\n
For more information about research offerings from Zacks Investment Research, visit Zacks.com <\/p>\n
<\/p>\n
More:<\/p>\n
The Edap Tms SA (EDAP) Stock Rating Decreased by the Zacks Investment Research - DailyQuint<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Edap Tms S.A. (NASDAQ:EDAP) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research note issued to investors on Tuesday Continue reading